Current targeting of NR4A1 is still at pre-clinical stages, but the genetic evidence has strongly established NR4A1 as a good target for immune therapeutics to eliminate Tregs and/or rejuvenate Texh cells, as well as targeting the invasive and metabolic pathways in cancer cells. Here, NR4A1 is linked to cancer.